{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=64", "query": { "condition": "Lymphoid", "page": 64 }, "page_size": 10 }, "pagination": { "page": 64, "page_size": 10, "total_count": 3083, "total_pages": 309, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=65&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=63&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T23:23:26.075Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02623920", "title": "Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma", "Mediastinal Large B-cell Lymphoma", "Grey Zone Lymphoma", "High Grade B Cell Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Brentuximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-12-16", "completion_date": "2017-05-17", "has_results": false, "last_update_posted_date": "2017-05-19", "last_synced_at": "2026-11-12T23:23:26.075Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02623920" }, { "nct_id": "NCT01630564", "title": "Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion", "type": "PROCEDURE" }, { "name": "Umbilical Cord Blood-Derived Lymphocyte Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": null, "sex": "ALL", "summary": "6 Months and older" }, "enrollment_count": 2, "start_date": "2013-03-11", "completion_date": "2018-05-30", "has_results": false, "last_update_posted_date": "2018-11-13", "last_synced_at": "2026-11-12T23:23:26.075Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01630564" }, { "nct_id": "NCT04810052", "title": "Positive Activities Intervention to Improve Quality of Life in Collectivist Culture Cancer Patients and Their Caregivers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Behavioral Intervention", "type": "BEHAVIORAL" }, { "name": "Interview", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2021-05-18", "completion_date": "2025-09-19", "has_results": false, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-11-12T23:23:26.075Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04810052" }, { "nct_id": "NCT00086203", "title": "Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Talabostat mesylate (PT-100) tablets", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Point Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2015-03-25", "last_synced_at": "2026-11-12T23:23:26.075Z", "location_count": 19, "location_summary": "Little Rock, Arkansas • Ocala, Florida • St. Petersburg, Florida + 16 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Ocala", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00086203" }, { "nct_id": "NCT01456182", "title": "Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell" ], "interventions": [ { "name": "AFX-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Afexa Life Sciences Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2011-12", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2012-01-25", "last_synced_at": "2026-11-12T23:23:26.075Z", "location_count": 3, "location_summary": "Ann Arbor, Michigan • Winston-Salem, North Carolina • Greenville, South Carolina", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01456182" }, { "nct_id": "NCT07583810", "title": "Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma", "Gastric Mucosa-Associated Lymphoid Tissue Lymphoma", "Marginal Zone Lymphoma", "Nodal Marginal Zone Lymphoma", "Splenic Marginal Zone Lymphoma", "Lymphoma", "Extranodal Marginal Zone Lymphoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nemtabrutinib", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2026-10-23", "completion_date": "2030-09-25", "has_results": false, "last_update_posted_date": "2026-10-29", "last_synced_at": "2026-11-12T23:23:26.075Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07583810" }, { "nct_id": "NCT04887259", "title": "Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Multiple Myeloma", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "LAVA-051", "type": "BIOLOGICAL" }, { "name": "Interleukin 2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Lava Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-07-12", "completion_date": "2023-09-06", "has_results": false, "last_update_posted_date": "2025-01-27", "last_synced_at": "2026-11-12T23:23:26.075Z", "location_count": 5, "location_summary": "Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04887259" }, { "nct_id": "NCT03448991", "title": "Effect of NPO Time and Type of Food Intake on Preoperative Residual Gastric Content and pH", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fasting", "Pediatric ALL" ], "interventions": [], "intervention_types": [], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "ALL", "summary": "Up to 17 Years" }, "enrollment_count": 150, "start_date": "2018-08-24", "completion_date": "2019-12-11", "has_results": false, "last_update_posted_date": "2021-01-19", "last_synced_at": "2026-11-12T23:23:26.075Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03448991" }, { "nct_id": "NCT00098423", "title": "Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts in Transformation", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2004-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-11-12T23:23:26.075Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098423" }, { "nct_id": "NCT05969860", "title": "At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Anal Carcinoma", "Advanced Biliary Tract Carcinoma", "Advanced Bladder Carcinoma", "Advanced Breast Carcinoma", "Advanced Carcinoid Tumor", "Advanced Cervical Carcinoma", "Advanced Colorectal Carcinoma", "Advanced Gastric Carcinoma", "Advanced Glioblastoma", "Advanced Head and Neck Carcinoma", "Advanced HER2 Positive Breast Carcinoma", "Advanced Lung Carcinoma", "Advanced Lung Small Cell Carcinoma", "Advanced Malignant Germ Cell Tumor", "Advanced Malignant Solid Neoplasm", "Advanced Neuroendocrine Carcinoma", "Advanced Ovarian Carcinoma", "Advanced Pancreatic Carcinoma", "Advanced Prostate Small Cell Neuroendocrine Carcinoma", "Advanced Prostate Carcinoma", "Hematopoietic and Lymphoid System Neoplasm", "Multiple Myeloma", "Myelodysplastic Syndrome", "Advanced Basal Cell Carcinoma", "Advanced Cholangiocarcinoma", "Advanced Endometrial Carcinoma", "Advanced Esophageal Carcinoma", "Advanced Fallopian Tube Carcinoma", "Advanced Hepatocellular Carcinoma", "Advanced Liver Carcinoma", "Advanced Lymphoma", "Advanced Malignant Testicular Neoplasm", "Advanced Melanoma", "Advanced Merkel Cell Carcinoma", "Advanced Penile Carcinoma", "Advanced Primary Malignant Central Nervous System Neoplasm", "Advanced Renal Cell Carcinoma", "Advanced Sarcoma", "Advanced Skin Squamous Cell Carcinoma", "Advanced Urethral Carcinoma", "Advanced Vaginal Carcinoma", "Advanced Vulvar Carcinoma", "Advanced Appendix Carcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Clinical Encounter", "type": "PROCEDURE" }, { "name": "Home Health Encounter", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2023-09-21", "completion_date": "2028-03-22", "has_results": false, "last_update_posted_date": "2026-11-06", "last_synced_at": "2026-11-12T23:23:26.075Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Grand Forks, North Dakota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Grand Forks", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05969860" } ] }